A Double-blind, Randomised, Placebo-controlled, Phase 2b/3 Adaptive Clinical Trial Investigating the Efficacy and Safety of Selepressin as Treatment for Patients with Vasopressor-dependent Septic Shock
Mark Tidswell, MD
Baystate Medical Center
759 Chestnut Street
Springfield, MA 01199
The purpose of this study is to investigate the efficacy and safety of multiple dosing regimens of selepressin and to confirm the efficacy and safety of one dosing regimen in treatment of adult patients with septic shock requiring vasopressor.
Eligible participants must be at least 18 years of age with proven or suspected infection as well as septic shock.